LAUSR

168 BRIEF CO-ADMINISTRATION OF IDELALISIB MAY IMPROVE THE LONGTERM EFFICACY OF FRONTLINE CHEMOIMMUNOTHERAPY IN CHRONIC LYMPHOCYTIC LEUKAEMIA: 3-YEAR FOLLOW-UP FROM THE RIALTO TRIAL A. Pettitt | N. Kalakonda | S. Cicconi | C. Murphy | G. Menon | S.E. Coupland | M. Oates | K. Lin | C. Pocock | S. Jenkins | A. Schuh | F. Wandroo | S. Rassam | A.S. Duncombe | P. Cervi | S. Paneesha | M. Aldouri | C. Fox | C. Knechtli | M. Hamblin | D. Turner | P. Hillmen Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, United Kingdom; CR-UK Liverpool Cancer Trials Unit, University of Liverpool, Liverpool, United Kingdom; Liverpool Clinical Laboratories, Haemato-Oncology Diagnostic Service, Liverpool, United Kingdom; Liverpool Clinical Laboratories, Department of Blood Sciences, Liverpool, United Kingdom; Department of Haematology, Kent & Canterbury Hospital, Canterbury, United Kingdom; Russells Hall Hospital, Haematology Unit, Dudley, United Kingdom; Department of Oncology, University of Oxford, Oxford, United Kingdom; Department of Haematology, Sandwell Hospital, Birmingham, United Kingdom; Department of Haematology, Maidstone Hospital, Maidstone, United Kingdom; Department of Haematology, University Hospital Southampton, Southampton, United Kingdom; Department of Haematology & Blood Transfusion, Southend Hospital, Southend, United Kingdom; Department of Haematology, Heartlands Hospital, Birmingham, United Kingdom; Department of Haematology, Medway Maritime Hospital, Gillingham, United Kingdom; Department of Clinical Haematology, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Department of Clinical Haematology, Royal United Hospital, Bath, United Kingdom; Department of Haematology, Colchester General Hospital, Colchester, United Kingdom; Oncology Unit, Torbay Hospital, Torquay, United Kingdom; Faculty of Medicine and Health, University of Leeds, Leeds, United Kingdom